KRAS and pancreatic ductal adenocarcinoma: Interestingly, we also showed that silencing of miR-92a-3p also increases BIM protein expression and sensitivity to cisplatin in another KRAS-driven tumor cell line model distinct from LUAD, the pancreatic ductal adenocarcinoma.